Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma

Author:

Wang Xiaojiang123,Sun Jiandong13,Liu Yue13,Lin Zihang13,Jiang Xia13,Ye Yuhong134,Lv Chengyu135,Lian Xiuli13,Xu Weiwei13,Luo Shanshan13,Liao Shumin13,Chen Zhangting13,Wang Shie13ORCID

Affiliation:

1. Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University Fujian Medical University Fuzhou China

2. Department of Molecular Pathology Fujian Medical University Cancer Hospital, Fujian Cancer Hospital Fuzhou China

3. Department of Histology and Embryology, School of Basic Medical Sciences Fujian Medical University Fuzhou China

4. Department of Pathology The First Affiliated Hospital of Fujian Medical University Fuzhou China

5. Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital Affiliated Hospital of Fujian Medical University Fuzhou China

Abstract

AbstractTRPS1 is aberrantly expressed in a variety of tumors, including breast, prostate, and gastric cancers, and is strongly associated with tumorigenesis or prognosis. However, the role of TRPS1 in high grade serous ovarian carcinoma (HGSC) is unknown. We investigated the relationship between TRPS1 expression and clinicopathology in HGSC patients. The tumor‐related regulatory mechanisms of TRPS1 was explored through in vivo and vitro experiments. The results showed that TRPS1 was highly expressed in HGSC compared to normal tissues. It was also linked to the cell proliferation index Ki67 and poor prognosis. In vivo experiments showed that knockdown of TRPS1 could inhibit tumor growth. In vitro experiments, knockdown of TRPS1 inhibited the proliferation of ovarian cancer cells. TRPS1 exerted its regulatory role as a transcription factor, binding to the PSAT1 promoter and promoting the expression of PSAT1 gene. Meanwhile, PSAT1 was positively correlated with CCND1 expression. These results suggest that TRPS1 affects HGSC proliferation and cell cycle by regulating PSAT1 and thus CCND1 expression.

Publisher

Wiley

Subject

Cancer Research,Oncology

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3